Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Steven C. QuayPresident & CEO | Atossa TherapeuticsATOS | Open-market buy | 25/05/21 | 25/05/22 | 11,239 sh | $0.88 | $9,890.32 | +422.7% |
H. Lawrence RemmelDirector | Atossa TherapeuticsATOS | Open-market buy | 25/03/26 | 25/03/28 | 10,000 sh | $0.70 | $7,000 | +3891.1% |
Jonathan FinnDirector | Atossa TherapeuticsATOS | Open-market buy | 24/04/10 | 24/04/11 | 25,000 sh | $1.77 | $44,250 | No record |
Gregory L. WeaverFormer EVP, CFO, & Director | Atossa TherapeuticsATOS | Open-market sale | 23/11/15 | 23/11/17 | 50,000 sh | $0.65 | $32,500 | −99.9% |
Gregory L. WeaverEVP & CFO | Atossa TherapeuticsATOS | Open-market buy | 23/06/20 | 23/06/20 | 50,000 sh | $0.97 | $48,500 | +90909.1% |